<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00670839</url>
  </required_header>
  <id_info>
    <org_study_id>2007-005023-15</org_study_id>
    <secondary_id>ANRS HB04 B-BOOST</secondary_id>
    <nct_id>NCT00670839</nct_id>
  </id_info>
  <brief_title>Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)</brief_title>
  <acronym>B-BOOST</acronym>
  <official_title>Open-label, Randomized, and Multicenter Phase III Clinical Trial Comparing Immunogenicity of Double-dose (40 µg at S0, S4 and S24), Versus Standard Dose Vaccination (20 µg at S0, S4 and S24), Against Hepatitis B Virus in HIV-1-infected Patients Without Any Previous Immune Response After Primary Immunization Plus One Single Boost</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MCM Vaccines B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV infected patients exposed to Hepatitis B virus are more susceptible to develop a chronic
      and severe liver disease, with a major risk of cirrhosis and liver cancer.

      However, immune response to standard Hepatitis B vaccination is decreased in HIV-infected
      patients, compared to non HIV-infected individuals, and, in case of response, its durability
      has to be carefully followed up. This study compares the efficacy of two strategies of
      revaccination in HIV-infected patients who didn't respond to previous hepatitis B
      vaccination. Failure is defined by two conditions: non response to the primary immunization
      (2 to 4 single-dose injections received before the screening visit) and failure to a single
      20 µg boost before being included in the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison of 2 revaccination strategies in randomized HIV-infected patients with T CD4 cell
      count above 200/mm3

      Intervention:

        1. Arm A: GenHevac-B® 20μg IM at M0, M1, M6

        2. Arm B: GenHevac-B® 40μg IM at M0, M1, M6
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of HIV-infected patients who seroconvert one month after the last vaccination. Seroconversion is defined as anti-HBs titers equal or above 10 mUI per ml</measure>
    <time_frame>one month after the last vaccination (week 28)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>According to the vaccine strategy (single-dose or double-dose), comparison of AbHBs titers, permanence of humoral response, intensity of clinical and biological events, and predicting factors related to seroconversion</measure>
    <time_frame>one month after the last injection ( week 28) and month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunological substudy: to understand genetic link between some alleles of HLA-DR and non-response to immunization</measure>
    <time_frame>at D0</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">178</enrollment>
  <condition>Hepatitis B</condition>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GenHevac-B 20 microgram intramuscular use at M0, M1 and M6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GenHevac-B 40 microgram intramuscular use at M0, M1 and M6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GenHevac-B</intervention_name>
    <description>1 intramuscular injection of Genhevac-B® 20μg on day zero, month 1,and month 6</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Sanofi Pasteur MSD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GenHevac-B</intervention_name>
    <description>2 intramuscular injections of Genhevac-B® 20μg on day zero, month 1,and month 6</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Sanofi Pasteur MSD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection

          -  T CD4 cell count number above 200 /mm3

          -  History of 2 to 4 injections of Hepatitis B vaccine, at any time in the past

          -  No history of Hepatitis B vaccination with a double-dose schedule

          -  No response to Hepatitis B vaccination: serology Hepatitis B negative (AgHBs, AbHBs
             and AbHBc negative) the previous twelve months and at the screening visit

          -  AbHBs titers below 10 IU/ml four weeks after the boost of Genhevac-B® 20μg preceding
             the randomization

          -  unchanged ARV treatment for the last 2 months for patients who are receiving ARV at
             the screening visit

          -  Undetectable HIV RNA for the last 6 months and on-going ARV for any patients with T
             CD4 cell level below 350/mm3

          -  HIV-1 plasma load below 100 000 copies per ml for patients without ARV

          -  Negative pregnancy test at the screening visit, and immediately before the Genhevac-B®
             20 µg boost injection preceding the randomization

        Exclusion Criteria:

          -  Acute cytolysis in the last 3 months with transaminases equal or above 5 times the
             upper limit of normal for HIV-HCV coinfected patients, or transaminases equal or above
             2 times the upper limit of normal for non coinfected patients

          -  Any vaccine received during the month preceding the inclusion

          -  History of hypersensitivity to any component of GenHevac-B

          -  acute opportunistic infection treated the month before the screening visit

          -  Severe and acute pyretic infection or unexplained fever the week before inclusion

          -  Hemopathy or solid-organ cancer

          -  Prothrombin factor equal or below 50% and/or platelets equal or below 50 000 per mm3

          -  Immunosuppressive treatment or general corticotherapy (equal or above 0,5 mg per kg
             per day during at least 7 days) in the last 6 months before the screening visit

          -  Immunomodulating treatment (interferon, interleukine-2,…) in the last 6 months before
             the screening visit

          -  Splenectomy

          -  Decompensated cirrhosis (Child Pugh B or C)

          -  Renal failure (creatinine clearance below 50 ml/mn)

          -  Other severe immunocompromised condition not related to HIV infection (solid-organ
             transplantation, chemotherapy in the last 6 months,….)

          -  Any participation to another clinical trial plan until Week 28
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Rey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital civil, Strasbourg, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabrice Carrat, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Inserm U707 Paris France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de Soins de l'Infection par le VIH NHC, Hôpitaux Universitaires Strasbourg, 1 place de l'hôpital</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091 Cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.anrs.fr</url>
  </link>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2008</study_first_submitted>
  <study_first_submitted_qc>May 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2008</study_first_posted>
  <last_update_submitted>August 8, 2013</last_update_submitted>
  <last_update_submitted_qc>August 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B vaccination</keyword>
  <keyword>GenHevac-B Pasteur</keyword>
  <keyword>HIV infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

